Skip to main content
Print Save

Generic Verquvo Availability

Last updated on Nov 7, 2023.

Verquvo is a brand name of vericiguat, approved by the FDA in the following formulation(s):

VERQUVO (vericiguat - tablet;oral)

Has a generic version of Verquvo been approved?

No. There is currently no therapeutically equivalent version of Verquvo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verquvo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent 10,736,896
    Issued: August 11, 2020
    Inventor(s): Follmann Markus & Stasch Johannes-Peter & Redlich Gorden & Ackerstaff Jens & Griebenow Nils & Kroh Walter & Knorr Andreas & Becker Eva-Maria & Wunder Frank & Li Volkhart Min-Jian & Hartmann Elke & Mittendorf Joachim & Schlemmer Karl-Heinz & Jautelat Rolf & Bierer Donald
    Assignee(s): ADVERIO PHARMA GMBH

    The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

    Patent expiration dates:

    • May 19, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent 11,439,642
    Issued: September 13, 2022
    Inventor(s): Follmann Markus & Stasch Johannes-Peter & Redlich Gorden & Ackerstaff Jens & Griebenow Nils & Kroh Walter & Knorr Andreas & Becker Eva-Maria & Wunder Frank & Li Volkhart Min-Jian & Hartmann Elke & Mittendorf Joachim & Schlemmer Karl-Heinz & Jautelat Rolf & Bierer Donald
    Assignee(s): ADVERIO PHARMA GMBH

    The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

    Patent expiration dates:

    • May 19, 2031
      ✓ 
      Patent use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent 8,420,656
    Issued: April 16, 2013
    Inventor(s): Follmann Markus & Stasch Johannes-Peter & Redlich Gorden & Ackerstaff Jens & Griebenow Nils & Kroh Walter & Knorr Andreas & Becker Eva-Maria & Wunder Frank & Li Volkhart Min-Jian & Hartmann Elke & Mittendorf Joachim & Schlemmer Karl-Heinz & Jautelat Rolf & Bierer Donald
    Assignee(s): Bayer Intellectual Property GmbH

    The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

    Patent expiration dates:

    • May 19, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent 8,921,377
    Issued: December 30, 2014
    Inventor(s): Follmann Markus & Stasch Johannes-Peter & Redlich Gorden & Ackerstaff Jens & Griebenow Nils & Kroh Walter & Knorr Andreas & Becker Eva-Maria & Wunder Frank & Li Volkhart Min-Jian & Hartmann Elke & Mittendorf Joachim & Schlemmer Karl-Heinz & Jautelat Rolf & Bierer Donald
    Assignee(s): Bayer Intellectual Property GmbH

    The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

    Patent expiration dates:

    • May 19, 2031
      ✓ 
      Patent use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
  • Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
    Patent 9,604,948
    Issued: March 28, 2017
    Inventor(s): Fey Peter & Grunenberg Alfons & Bierer Donald
    Assignee(s): ADVERIO PHARMA GMBH

    The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI)

    Patent expiration dates:

    • November 26, 2032
      ✓ 
      Patent use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted 5-flouro-1H-pyrazolopyridines and their use
    Patent 9,993,476
    Issued: June 12, 2018
    Inventor(s): Follmann Markus & Stasch Johannes-Peter & Redlich Gorden & Ackerstaff Jens & Griebenow Nils & Kroh Walter & Knorr Andreas & Becker Eva-Maria & Wunder Frank & Li Volkhart Min-Jian & Hartmann Elke & Mittendorf Joachim & Schlemmer Karl-Heinz & Jautelat Rolf & Bierer Donald
    Assignee(s): ADVERIO PHARMA GMBH

    The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

    Patent expiration dates:

    • May 19, 2031
      ✓ 
      Patent use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • January 19, 2026 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer